1,059 reports of this reaction
2.6% of all SOFOSBUVIR reports
#8 most reported adverse reaction
INSOMNIA is the #8 most commonly reported adverse reaction for SOFOSBUVIR, manufactured by Gilead Sciences, Inc.. There are 1,059 FDA adverse event reports linking SOFOSBUVIR to INSOMNIA. This represents approximately 2.6% of all 41,429 adverse event reports for this drug.
Patients taking SOFOSBUVIR who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for SOFOSBUVIR, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for SOFOSBUVIR:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 1,059 FDA reports for SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 2.6% of all adverse event reports for SOFOSBUVIR, making it a notable side effect.
If you experience insomnia while taking SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.